PTC Therapeutics, Inc. (PTCT): Operating Cash Flow
$711.20M
Year ended 2025-12-31
-$30.50M
Trailing 12 months to 2026-06-30
| Period ended | Operating Cash Flow | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $711.20M | n/m | 2026-02-19, From 2025-01-01 |
| 2024-12-31 | -$107.69M | n/m | 2026-02-19, From 2024-01-01 |
| 2023-12-31 | -$158.42M | n/m | 2026-02-19, From 2023-01-01 |
| 2022-12-31 | -$356.65M | n/m | 2025-02-27, From 2022-01-01 |
| 2021-12-31 | -$251.33M | n/m | 2024-02-29, From 2021-01-01 |
| 2020-12-31 | -$194.07M | n/m | 2023-02-21, From 2020-01-01 |
| 2019-12-31 | -$98.64M | n/m | 2022-02-22, From 2019-01-01 |
| 2018-12-31 | -$27.64M | n/m | 2021-02-25, From 2018-01-01 |
| 2017-12-31 | -$10.06M | n/m | 2020-03-02, From 2017-01-01 |
| 2016-12-31 | -$103.57M | n/m | 2019-03-01, From 2016-01-01 |
| 2015-12-31 | -$124.34M | n/m | 2018-03-06, From 2015-01-01 |
| 2014-12-31 | -$57.27M | n/m | 2017-03-16, From 2014-01-01 |
| 2013-12-31 | -$46.92M | n/m | 2016-02-29, From 2013-01-01 |
| 2012-12-31 | -$47.93M | n/m | 2015-03-02, From 2012-01-01 |
| 2011-12-31 | -$20.77M | n/a | 2014-03-06, From 2011-01-01 |
Operating Cash Flow at similar companies
| Company | Year ended | Operating Cash Flow | Change YoY |
|---|---|---|---|
| PTC Therapeutics, Inc. (PTCT) | 2025-12-31 | $711.20M | n/m |
| Phibro Animal Health Corp (PAHC) | 2026-06-30 | $68.95M | -13.9% |
| Alkermes plc. (ALKS) | 2025-12-31 | $520.75M | +18.6% |
| Sarepta Therapeutics, Inc. (SRPT) | 2025-12-31 | -$205.48M | n/m |
| Royalty Pharma plc (RPRX) | 2025-12-31 | $2.49B | -10.1% |
| Indivior Pharmaceuticals, Inc. (INDV) | 2025-12-31 | -$27.00M | n/m |
| Prestige Consumer Healthcare Inc. (PBH) | 2026-03-31 | $257.63M | +2.4% |
| Acadia Pharmaceuticals Inc (ACAD) | 2025-12-31 | $109.84M | -30.4% |
| Amneal Pharmaceuticals, Inc. (AMRX) | 2025-12-31 | $339.99M | +15.2% |
Compare PTCT, PAHC, ALKS, SRPT side by side · Screen every company in Pharmaceutical Preparations ↗